A BRAF mutation is a spontaneous change in the BRAF gene that makes it work incorrectly. A mutation causes the gene to turn on the protein and keep it on, which means certain cells get ongoing signals to keep dividing and no instructions on when to stop.

BRAF is a human gene that encodes a protein called B-Raf. The gene is also referred to as proto-oncogene B-Raf and v-Raf murine sarcoma viral oncogene homolog B , while the protein is more formally known as serine/threonine-protein kinase B-Raf .

In the human genome, the B-raf proto-oncogene (BRAF) gene is located on chromosome 7 (7q34) and encodes the BRAF protein, which is composed of 766 amino acids. While all RAF proteins can phosphorylate MEK (MEK1 and MEK2), BRAF has the strongest activation capacity.

2024年6月23日 · BRAF mutations are DNA changes in some cancer cells that can be treated with newer targeted therapies. BRAF mutations are found in roughly half of melanomas. Medications that target these mutations have significantly improved the survival rates of metastatic melanoma.

2024年4月16日 · In this review, we cover the current understanding of BRAF mutations and associated clinical characteristics in patients with metastatic NSCLC, approved and emerging treatment options, BRAF...

2024年1月26日 · In this Review, we describe the biochemical basis for oncogenic BRAF-induced activation of MAPK signalling and pan-cancer and lineage-specific mechanisms of intrinsic, adaptive and acquired...

In this review, we identify the mechanics of RAF signaling through the RAS/MAPK pathway, present existing data on single-agent and combination RAF targeting efforts, describe emerging combinations, summarize the toxicity of the various agents in clinical testing, and speculate as to where the field may be headed.

Gene ID: 673, updated on 8-Feb-2025. This gene encodes a protein belonging to the RAF family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which affects cell division, differentiation, and secretion.

2024年12月24日 · BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase) is a Protein Coding gene. Diseases associated with BRAF include Lung Cancer and Cardiofaciocutaneous Syndrome 1. Among its related pathways are IL-9 Signaling Pathways and Prolactin Signaling.

2025年2月28日 · BRAF (V-Raf murine sarcoma viral oncogene homolog B) mutation is an uncommon mutation. Mutated BRAF proteins cause cells to grow out of control. This can affect the lungs, leading to the ...

B-Raf is a key regulator of the ERK pathway and is mutationally activated in two-thirds of human melanomas. In this work, we have investigated the activation mechanism of B-Raf and characterized the roles of Ras and of B-Raf phosphorylation in this regulation.

B-Raf is one of the more commonly mutated proto-oncogenes implicated in the development of cancers. In this review, we consider the mechanisms and clinical impacts of B-Raf mutations in cancer and discuss the implications for the patient in melanoma, thyroid cancer and colorectal cancer, where B-Raf …

2019年2月26日 · BRAF encodes the B-Raf protein, which is involved in signal transduction inside cells. It catalyzes phosphorylation of serine and threonine on target proteins, converting adenosine...

B-raf, a new member of the raf family, is activated by DNA rearrangement. Complementary DNA clones of a putative transforming gene were isolated from NIH 3T3 cells transformed with human Ewing sarcoma DNA. The gene was termed B-raf because it is …

BRAF is one type of lung cancer biomarker. BRAF is the name of both a gene and a protein. The BRAF protein helps control cell growth. When there is a mutation in the BRAF gene, it creates an abnormal protein that sends signals that lead to uncontrolled cell growth and cancer.

B-Raf. Genes of the Raf family mediate cellular response to growth signals. Genetic and biochemical evidence indicates that B-Raf is the principal downstream effector of K-Ras. Activating mutations in the B-Raf gene occur only in colorectal tumours that do not carry mutations in the K-Ras gene.

2012年12月3日 · Vemurafenib is the first molecularly targeted therapy to be licensed in the US and Europe for treatment of advanced melanoma. Its mechanism of action involves selective inhibition of the mutated BRAF V600E kinase that leads to reduced signalling through the aberrant mitogen-activated protein kinase …

2002年12月1日 · BRAF encodes a RAS-regulated kinase that mediates cell growth and malignant transformation kinase pathway activation. Recently, we have identified activating BRAF mutations in 66% of melanomas and a smaller percentage of many other human cancers.

2025年3月7日 · Targeted Oncology: Please explain the background, methods, and design of the BREAKWATER trial. Kopetz: The BREAKWATER study was a randomized phase 3 study that was run internationally.It was evaluating the efficacy of targeted therapy combined with chemotherapy in patients with metastatic BRAF V600E colorectal cancer.These were …

Approximately 50% of melanomas harbor activating (V600) mutations in the serine–threonine protein kinase B-RAF (BRAF). The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced tumor regressions in patients with BRAF V600–mutant metastatic ...